Calithera Biosciences, Inc. (NASDAQ:CALA) – Equities researchers at Leerink Swann decreased their Q3 2017 earnings per share estimates for shares of Calithera Biosciences in a research note issued to investors on Tuesday. Leerink Swann analyst J. Chang now anticipates that the biotechnology company will post earnings per share of ($0.27) for the quarter, down from their previous estimate of ($0.21). Leerink Swann also issued estimates for Calithera Biosciences’ Q4 2017 earnings at ($0.30) EPS, FY2017 earnings at ($0.95) EPS and FY2018 earnings at ($0.98) EPS.

Calithera Biosciences (NASDAQ:CALA) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.15) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.14. The firm had revenue of $7.26 million for the quarter, compared to the consensus estimate of $4.80 million.

COPYRIGHT VIOLATION NOTICE: “Calithera Biosciences, Inc. to Post Q3 2017 Earnings of ($0.27) Per Share, Leerink Swann Forecasts (CALA)” was reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/calithera-biosciences-inc-to-post-q3-2017-earnings-of-0-27-per-share-leerink-swann-forecasts-cala/1471888.html.

CALA has been the topic of several other reports. BidaskClub raised shares of Calithera Biosciences from a “hold” rating to a “buy” rating in a research note on Friday, July 7th. Zacks Investment Research cut shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 13th. Wells Fargo & Company reissued an “outperform” rating and set a $20.00 price target (up from $15.00) on shares of Calithera Biosciences in a research note on Tuesday, June 6th. Finally, HC Wainwright reissued a “buy” rating and set a $19.00 price target (up from $14.00) on shares of Calithera Biosciences in a research note on Monday, June 12th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $15.50.

Shares of Calithera Biosciences (NASDAQ CALA) opened at 12.05 on Friday. The company’s 50-day moving average price is $15.91 and its 200 day moving average price is $12.67. Calithera Biosciences has a one year low of $2.20 and a one year high of $20.05. The company’s market cap is $427.49 million.

In other Calithera Biosciences news, VP Keith Orford sold 2,120 shares of the firm’s stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $18.31, for a total value of $38,817.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 3,470 shares of company stock worth $61,817. Insiders own 16.30% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc acquired a new position in shares of Calithera Biosciences during the second quarter worth about $120,000. Raymond James Financial Services Advisors Inc. acquired a new position in shares of Calithera Biosciences during the first quarter worth about $117,000. Nationwide Fund Advisors acquired a new position in shares of Calithera Biosciences during the first quarter worth about $131,000. KCG Holdings Inc. acquired a new position in shares of Calithera Biosciences during the first quarter worth about $144,000. Finally, Paloma Partners Management Co acquired a new position in shares of Calithera Biosciences during the first quarter worth about $160,000. 54.51% of the stock is currently owned by hedge funds and other institutional investors.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.